 | | Vol. 11.42 – 6 November, 2020 |
| |
|
|
| Using large patient datasets, patient-derived organoids and cancer cell lines, researchers identified mSWI/SNF subunits that were deregulated in neuroendocrine prostate cancer and demonstrated that SMARCA4 overexpression was associated with aggressive disease.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists found that Cisplatin or Carboplatin, currently used in chemotherapy/radiation therapy to suppress tumor progression, could restore the Enzalutamide (Enz) sensitivity in multiple Enz-resistant castration-resistant prostate cancer cells via directly degrading/suppressing ARv7.
[Cell Death & Disease] |
|
|
|
| Researchers demonstrated that miR-671-5p promoted prostate cancer development and metastasis by suppressing the NFIA/CRYAB axis.
[Cell Death & Disease] |
|
|
|
| Investigators showed that cancer-associated fibroblast-secreted exosomal miR-423-5p promoted chemotherapy resistance in prostate cancer by targeting GREM2 through the TGF-β pathway.
[Experimental and Molecular Medicine] |
|
|
|
| The authors report some initial observations that provided new insights into zinc processing during glucose-stimulated zinc secretion in the immortalized human prostate epithelial cell line, PNT1A.
[Molecular Imaging and Biology] |
|
|
|
| The levels of AFAP1-AS1 and FKBP1A were upregulated in prostate cancer (PCa) tissues and cells, as well as PTX-resistant PCa cells, while the expression of miR-195-5p was declined.
[Cancer Biology & Therapy] |
|
|
|
| Investigators found that lysophosphatidylcholine acyltransferase1 (LPCAT1) overexpression enhanced the proliferation, migration, and invasion of castration resistant prostate cancer (CRPC) cells both in vitro and in vivo. Silencing of LPCAT1 reduced the proliferation and the invasive capabilities of CRPC cells.
[PLoS One] |
|
|
|
|
| Intraductal carcinoma of the prostate is an aggressive type of prostate cancer associated with high risk for local recurrence and distant metastasis. Scientists discuss pathogenesis, biomarkers, differential diagnoses, and therapeutic strategies for this tumor.
[European Urology] |
|
|
|
| The authors explore insights into the mechanisms by which hypersialylation plays a role in promoting metastasis, and explore the current state of sialyltransferase inhibitor development.
[British Journal of Cancer] |
|
|
|
| Investigators provide an overview of epigenetic alterations in the development and progression of prostate cancer, focusing on deoxyribonucleic acid methylation and histone modifications.
[International Journal of Urology] |
|
|
|
|
| Exelixis, Inc. announced enrollment of the first patient into the dose-escalation cohort of the combination arm of the Phase I trial evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of XL092 alone and in combination with atezolizumab in patients with advanced solid tumors, including hormone-receptor positive breast cancer and metastatic castration-resistant prostate cancer.
[Exelixis, Inc.] |
|
|
|
|
| April 9 – April 14, 2021
Washington, DC, United States |
|
|
|
|
|
| | IRCCS Candiolo Cancer Institute – Candiolo, Italy |
|
|
|
| | Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
| | University of Southern Denmark – Odense M, Denmark |
|
|
|
| | University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | Pfizer – Collegeville, Pennsylvania, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
